Third-line salvage chemotherapy in Hodgkin's disease
- PMID: 2579440
Third-line salvage chemotherapy in Hodgkin's disease
Abstract
CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical